Cloning

Recreating the Earliest Stages of Life

Retrieved on: 
Friday, April 23, 2021
Biology, Developmental biology, Branches of biology, Life sciences, Embryo, Biotechnology, Stem cells, Cloning, Induced stem cells

b'SAN FRANCISCO, April 23, 2021 /PRNewswire/ -- In their effort to understand the very earliest stages of life and how they can go wrong, scientists are confronted with ethical issues surrounding the use of human embryos.

Key Points: 
  • b'SAN FRANCISCO, April 23, 2021 /PRNewswire/ -- In their effort to understand the very earliest stages of life and how they can go wrong, scientists are confronted with ethical issues surrounding the use of human embryos.
  • The use of animal embryos is also subject to restrictions rooted in ethical considerations.
  • "Using this model, we will be able to dissect the molecular events that take place during these early stages, and the signals that the different embryonic cells send to each other.
  • Gladstone is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease.

NanoMosaic Installs Wide Dynamic Range Proteomic Beta System at The New York Stem Cell Foundation Research Institute (NYSCF)

Retrieved on: 
Tuesday, April 6, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell, Proteomics, Omics, Susan L. Solomon

NEW YORK, April 6, 2021 /PRNewswire/ --NanoMosaic, the pioneer and leader in nanoneedle (MosaicNeedle) detection for proteomics and genomics, has installed its end-user fully customizable, nanoneedle proteomic beta system, "Tessie," at its second test site, the New York Stem Cell Foundation Research Institute (NYSCF).

Key Points: 
  • NEW YORK, April 6, 2021 /PRNewswire/ --NanoMosaic, the pioneer and leader in nanoneedle (MosaicNeedle) detection for proteomics and genomics, has installed its end-user fully customizable, nanoneedle proteomic beta system, "Tessie," at its second test site, the New York Stem Cell Foundation Research Institute (NYSCF).
  • The New York Stem Cell Foundation (NYSCF) Research Institute is an independent non-profit organization accelerating cures and better treatments for patients through stem cell research.
  • The NYSCF Research Institute is an acknowledged world leader in stem cell research and in the development of pioneering stem cell technologies, including the NYSCF Global Stem Cell Array, which is used to create cell lines for laboratories around the globe.
  • The NanoMosaic platform, Tessie, enables coverage of the largest dynamic range while maintaining high sensitivity, multiplexing capabilities and label-free assays.

Berkeley Lights Announces Opto™ Assure For Early Manufacturability Assessment of Antibody Therapeutics

Retrieved on: 
Monday, April 5, 2021
Branches of biology, Cloning, Plant reproduction, Biology, Immunology, Cell biology, Clone, Vegetative reproduction, Clonal, Propagation of grapevines

With Opto Assure, customers can rapidly select clonal cell lines with favorable manufacturability profiles, leading to decreased scale-up costs and better downstream products.

Key Points: 
  • With Opto Assure, customers can rapidly select clonal cell lines with favorable manufacturability profiles, leading to decreased scale-up costs and better downstream products.
  • Berkeley Lights enhances its technology leadership position in cell line development by going beyond titer assessment in the clone selection process.
  • Opto Assure helps minimize risk of costly late stage failures by identifying clones early on that secrete product with high yield and desired quality.
  • The Berkeley Lights Platform and the Berkeley Lights Beacon and Lightning systems and Culture Station instrument are FOR RESEARCH USE ONLY.

Gaensel Energy Group, Inc. (GEGR) Acquires SSCB Swiss Stem Cells Biotech, the Only Private Stem Cell Biobank in Switzerland

Retrieved on: 
Wednesday, March 17, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell

SSCB is a worldrenowned participant in Stem Cell Technology and places Gaensel in the front of this exciting and revolutionary health technology.

Key Points: 
  • SSCB is a worldrenowned participant in Stem Cell Technology and places Gaensel in the front of this exciting and revolutionary health technology.
  • SSCB Swiss Stem Cells Biotech SA is a Biotech Company; SSCB was born in 2005 as a spin-off of Cardiocentro Ticino of Lugano - Switzerland and is also present with other offices in Italy, Spain, Albania and Balkan countries.
  • SSCB was founded as a private bank for the cryopreservation of human stem cells obtained from blood and cord tissue for both autologous and allogeneic intra-family use.
  • SSCB receives regular inspections by SwissMedic, Swiss Institute for Therapeutic Products, and FACT-NetCord to process and store stem cells in their laboratories.

Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

Retrieved on: 
Monday, March 15, 2021
Biotechnology, Other Health, Health, Clinical trials, Oncology, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Blood, Cloning, Developmental biology, Cord blood, Guo Mei, Induced stem cells, Omidubicel, Gamida Cell

In the study, treatment with omidubicel showed faster hematopoietic recovery, fewer bacterial and viral infections and fewer days in hospital.

Key Points: 
  • In the study, treatment with omidubicel showed faster hematopoietic recovery, fewer bacterial and viral infections and fewer days in hospital.
  • Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases.
  • 1 Gamida Cell press release, Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic Malignancies, issued May 12, 2020.
  • Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide.

Kadimastem Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use in Drug Screening and the Treatment of ALS

Retrieved on: 
Tuesday, March 9, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell, Amyotrophic lateral sclerosis

Kadimastem's flagship product, AstroRx, is comprised of a differentiated cell population of human astrocytes derived from human pluripotent stem cells and is in clinical development as a therapeutic treatment for ALS.

Key Points: 
  • Kadimastem's flagship product, AstroRx, is comprised of a differentiated cell population of human astrocytes derived from human pluripotent stem cells and is in clinical development as a therapeutic treatment for ALS.
  • Kadimastem recently announced encouraging results of the Cohort B of its Phase 1/2a Clinical Trial of AstroRx for ALS.
  • The technology was first initiated at the Weizmann Institute of Science while Professor Michel Revel, the co-founder of Kadimastem, was a principal investigator there.
  • Kadimastem CEO Asaf Shiloni said,"The patent granted by the Israel Patent Officeis a significant step forward towards bringing AstroRx to market for the benefit of ALS patients worldwide.

Stem Cells Market Size Worth $18.4 Billion By 2028 | CAGR: 8.8%: Grand View Research, Inc.

Retrieved on: 
Tuesday, March 9, 2021
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Developmental biology, Cloning, Mesenchymal stem cell, Trophoblast, Stem-cell therapy, Adult stem cell

SAN FRANCISCO, March 9, 2021 /PRNewswire/ -- The global stem cells market size is expected to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, March 9, 2021 /PRNewswire/ -- The global stem cells market size is expected to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc.
  • The researchers discovered a new way for creating induced trophoblast stem cells which can be used for making placenta cells.
  • The patients received a single infusion of mesenchymal stem cells (MSCs) which was found to be effective in developing an immune response.
  • Grand View Research has segmented the global stem cells market on the basis of product, application, technology, therapy, and region:
    Stem Cells Product Outlook (Revenue, USD Million, 2017 - 2028)

Stem Cells Market Size Worth $18.4 Billion By 2028 | CAGR: 8.8%: Grand View Research, Inc.

Retrieved on: 
Tuesday, March 9, 2021
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Developmental biology, Cloning, Mesenchymal stem cell, Trophoblast, Stem-cell therapy, Adult stem cell

SAN FRANCISCO, March 9, 2021 /PRNewswire/ -- The global stem cells market size is expected to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, March 9, 2021 /PRNewswire/ -- The global stem cells market size is expected to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc.
  • The researchers discovered a new way for creating induced trophoblast stem cells which can be used for making placenta cells.
  • The patients received a single infusion of mesenchymal stem cells (MSCs) which was found to be effective in developing an immune response.
  • Grand View Research has segmented the global stem cells market on the basis of product, application, technology, therapy, and region:
    Stem Cells Product Outlook (Revenue, USD Million, 2017 - 2028)

Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline

Retrieved on: 
Wednesday, March 3, 2021
Branches of biology, Life sciences, Biology, Stem cells, Biotechnology, Induced stem cells, Cell biology, Cloning, Induced pluripotent stem cell, Therapy, IPSC, Cancer immunotherapy

PHILADELPHIA, March 3, 2021 /PRNewswire/ -- Century Therapeutics , a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the closing of a $160 million Series C financing.

Key Points: 
  • PHILADELPHIA, March 3, 2021 /PRNewswire/ -- Century Therapeutics , a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the closing of a $160 million Series C financing.
  • Eli Casdin, Founder and Chief Investment Officer of Casdin Capital will be joining the Century Therapeutics Board of Directors.
  • Funds raised will help advance Century's rich pre-clinical pipeline, which includes multiple iPSC-derived CAR-iT and CAR-iNK cell products.
  • Century Therapeutics is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first-generation cell therapies.

Cord Blood Banking Leader Cryo-Cell International Enters Into An Exclusive License Agreement with Duke University

Retrieved on: 
Friday, February 26, 2021
Branches of biology, Biology, Stem cells, Life sciences, Blood, Childbirth, Cloning, Cryo-Cell International, Cord blood, Cord blood bank, Draft:Americord Registry

The agreement grants Cryo-Cell the rights to proprietary processes and regulatory data related to cord blood and cord tissue developed at Duke.

Key Points: 
  • The agreement grants Cryo-Cell the rights to proprietary processes and regulatory data related to cord blood and cord tissue developed at Duke.
  • These treatments utilize the unique immunomodulatory and potential regenerative properties derived from cord blood and cord tissue.
  • Under the agreement, Cryo-Cell has been granted exclusive commercial rights to Dukes intellectual property assets, FDA regulatory data, clinical expertise and manufacturing protocols associated with various applications of cord blood and cord tissue stem cells.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.